Company Overview of Takeda Pharmaceuticals International GmbH
Takeda Pharmaceuticals International GmbH manufactures and markets patented products, branded generics, and over-the-counter products that treat patients in various therapeutic areas in Asia, North America, Europe, Latin America, the Russian Federation-CIS, China, and internationally. It offers products in the therapeutic areas of cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine (gastrointestinal and genitourinary), and vaccines. The company also provides clinical development, contract manufacturing, product launch, packaging, and process optimization and formulation services. Takeda Pharmaceuticals International GmbH was formerly k...
Founded in 1874
Key Executives for Takeda Pharmaceuticals International GmbH
Corporate Officer and President of Europe & Canada Business Unit
Head of Commercial Operations - Emerging Markets
Executive Vice President of Human Resources and IS/IT
Director of External Communications
Compensation as of Fiscal Year 2015.
Takeda Pharmaceuticals International GmbH Key Developments
Takeda Pharmaceuticals International GmbH Announces Vedolizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
May 19 15
Takeda Pharmaceuticals International GmbH announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease (CD) were presented at the 2015 Digestive Disease Week Annual Meeting in Washington, D.C. Twelve Takeda-sponsored presentations, including one oral presentation, were featured during the meeting May 16-19, 2015. The presentations included data from the Phase 3 pivotal studies GEMINI 1 (UC) and GEMINI 2 (CD), as well as interim data from the ongoing, open-label extension study GEMINI LTS. The GEMINI 1 and 2 studies are two randomized double-blind, placebo-controlled studies examining the efficacy and safety of vedolizumab for induction and maintenance in adult patients with moderately to severely active UC and CD, respectively. GEMINI LTS is a Phase 3, ongoing, open-label extension study examining the long-term safety and efficacy of vedolizumab for the treatment of adults with moderately to severely active UC and CD. Findings from an analysis of cost per-clinical-outcome for the treatment of moderately to severely active UC with biologic therapy were highlighted during an oral presentation on Saturday, May 16, 2015, as part of a larger session titled 'Bending the Cost Curve in Gastroenterology'.
Takeda Pharmaceuticals International GmbH Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM
Feb 18 15
Takeda Pharmaceuticals International GmbH Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Jane Atkins, Global Licensing & BD, Director, Search & Evaluation.
Takeda Pharmaceutical International GmbH Announces Results of the REACT Study Demonstrating Daxas
Feb 13 15
Takeda Pharmaceutical International GmbH announced results of the REACT study demonstrating Daxas(roflumilast) significantly reduced exacerbations and hospitalizations in patients with severe chronic obstructive pulmonary disease (COPD), who are at risk of frequent and severe exacerbations despite already receiving inhalation therapy with ICS/LABA combinations or triple (LAMA/ICS/LABA) therapy. The study showed that roflumilast significantly reduced the rate of severe exacerbations by 24.3% (p=0.0175) and those requiring hospitalization by 23.9% (p=0.0209), reducing the clinical and economic burden of this disease. In patients receiving triple therapy, roflumilast significantly reduced the rate of severe exacerbations by 23.3%(p=0.0406), indicating how patients with severe COPD may benefit most from the addition of roflumilast to their therapeutic regimen. These results have been published online in The Lancet. To prevent exacerbations and possible hospitalization, patients with severe COPD are treated with inhaled long-acting muscarinic antagonist alone and/or a fixed combination of inhaled corticosteroids/long-acting ß2-agonists (ICS/LABA). Despite access to these inhaled medications, a significant number of COPD patients still suffer from frequent exacerbations, impacting their overall health and accelerating lung function decline, leading to substantial morbidity and mortality. Already approved as an add-on therapy to long acting bronchodilators for severe COPD, the double-blind REACT study investigated roflumilast as an effective add-on therapy for the reduction of exacerbations, improved lung function and major adverse cardiac events in patients not adequately controlled with ICS/LABA combinations or triple LAMA/ICS/LABA therapy in maximal approved dosage. In the overall study population there was a reduction in the rate of moderate-to-severe exacerbations by 13.2%(p=0.0529) using a Poisson regression analysis and by 14.2%(p=0.0424) in a predefined sensitivity analysis using negative binomial regression, when compared with the placebo. Roflumilast showed a statistically significant improvement in lung function, with a 56 mL (p<0.0001) increase in post-bronchodilator FEV1 and 92 mL increase in FVC, compared to placebo.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|